Abstract
In Japan there has been a rapid increase in transcatheter aortic valve implantation (TAVI) patients and centers since the introduction of TAVI into clinical practice on October 2013. TAVI has become a safe and indispensable treatment option for patients with severe symptomatic aortic stenosis who are at high or prohibitive surgical risk. Surgical aortic valve replacement (SAVR) remains the gold standard for patients at low or intermediate operative risk. However, TAVI has currently emerged as a qualified alternative to SAVR in the treatment of those patients although the long-term durability of TAVI devices remain unanswered. Here, we will focus on the current status and future perspectives for TAVI procedures.
